User contributions for Rithish Nimmagadda
A user with 125 edits. Account created on 1 May 2024.
24 June 2024
- 00:3900:39, 24 June 2024 diff hist +10 Cardiac amyloidosis medical therapy No edit summary current Tag: Manual revert
- 00:3800:38, 24 June 2024 diff hist +1,100 Cardiac amyloidosis medical therapy →Treatment of Underlying Disease Tag: Manual revert
- 00:3700:37, 24 June 2024 diff hist −9 Cardiac amyloidosis natural history, complications and prognosis No edit summary current
- 00:3400:34, 24 June 2024 diff hist +10 Cardiac amyloidosis natural history, complications and prognosis No edit summary
- 00:2200:22, 24 June 2024 diff hist +10 Cardiac amyloidosis medical therapy No edit summary
- 00:2100:21, 24 June 2024 diff hist +1,103 Cardiac amyloidosis medical therapy →Treatment of Underlying Disease
23 June 2024
- 18:0518:05, 23 June 2024 diff hist −50 User:Rithish Nimmagadda No edit summary
- 18:0418:04, 23 June 2024 diff hist +14 User:Rithish Nimmagadda →Pages Co-authored/Collaborated
- 18:0318:03, 23 June 2024 diff hist −3 Migraine secondary prevention No edit summary current
- 18:0318:03, 23 June 2024 diff hist +233 Migraine secondary prevention No edit summary
- 18:0218:02, 23 June 2024 diff hist 0 Migraine secondary prevention No edit summary
- 18:0118:01, 23 June 2024 diff hist +535 Migraine secondary prevention No edit summary
- 17:5517:55, 23 June 2024 diff hist +9 Migraine No edit summary current
- 17:5417:54, 23 June 2024 diff hist −2 Migraine secondary prevention →First-line agents
- 17:5217:52, 23 June 2024 diff hist +12 Migraine secondary prevention No edit summary
- 17:5117:51, 23 June 2024 diff hist −8 Migraine secondary prevention No edit summary Tag: Manual revert
- 17:5117:51, 23 June 2024 diff hist +8 Migraine secondary prevention No edit summary
- 17:4917:49, 23 June 2024 diff hist +1,551 Migraine secondary prevention No edit summary
19 June 2024
- 00:5400:54, 19 June 2024 diff hist +49 Autoimmune hepatitis medical therapy No edit summary current
18 June 2024
- 23:4823:48, 18 June 2024 diff hist +53 User:Rithish Nimmagadda No edit summary
- 23:4723:47, 18 June 2024 diff hist +11 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 23:4623:46, 18 June 2024 diff hist +46 User:Rithish Nimmagadda No edit summary
- 23:4523:45, 18 June 2024 diff hist +9 Eosinophilic esophagitis medical therapy No edit summary current
- 23:4423:44, 18 June 2024 diff hist +264 Eosinophilic esophagitis medical therapy →Medical Therapy
- 23:3923:39, 18 June 2024 diff hist +679 Eosinophilic esophagitis medical therapy →Medical Therapy
2 June 2024
- 23:1923:19, 2 June 2024 diff hist +14 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 23:1923:19, 2 June 2024 diff hist +11,398 N Iptacopa Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=iptacopa |aOrAn=a |drugClass=complement factor B inhibitor. |indicationType=treatment |indication=adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions in adults with PNH (incidence ≥10%) were headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, and rash. |blackBoxWarningTitle=Serious Infecti..." current
21 May 2024
- 22:0122:01, 21 May 2024 diff hist +1,587 Vonoprazan, amoxicillin, and clarithromycin No edit summary current
- 21:5821:58, 21 May 2024 diff hist −12 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 18:3518:35, 21 May 2024 diff hist +47 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 18:3518:35, 21 May 2024 diff hist +14 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 18:3318:33, 21 May 2024 diff hist +7,024 N Vonoprazan, amoxicillin, and clarithromycin Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=vonoprazan, amoxicillin, and clarithromycin |aOrAn=a |drugClass=Potassium-competitive acid blocker |indicationType=treatment |indication=- erosive esophagitis (all grades) and relief of heartburn associated with erosive esophagitis in adults. ,Helicobacter pylori Infection |adverseReactions=-Common adverse reactions (≥2%) with vonoprazan when used for healing of erosive esophagitis: gastritis, diarrhea, abdom..."
- 17:0417:04, 21 May 2024 diff hist +19 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 16:5916:59, 21 May 2024 diff hist +4,566 N Pirtobrutinib Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=pirtobrutinib |aOrAn=an |drugClass=noncovalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). |indicationType=treatment |indication=elapsed or refractory MCL in adults who have received at least 2 lines of prior systemic therapy, including a BTK inhibitor; designated an orphan drug by FDA for treatment of MCL and also in treatment of CLL or SLL in adults who have received at least 2 prior lines of th..." current
- 00:1200:12, 21 May 2024 diff hist +313 Elacestrant No edit summary current
- 00:1000:10, 21 May 2024 diff hist +17 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 00:0900:09, 21 May 2024 diff hist +2,860 N Elacestrant Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=elacestrant |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer that has progressed following ≥1 line of endocrine-based therapy in postmenopausal women or adult men. |fdaLIADAdult=Dosage of elacestrant hydro..."
20 May 2024
- 23:0723:07, 20 May 2024 diff hist +25 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 23:0723:07, 20 May 2024 diff hist +7,709 N Velmanase alfa-tycv Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac..." current
- 20:3620:36, 20 May 2024 diff hist −296 Retifanlimab-dlwr No edit summary current
- 20:3320:33, 20 May 2024 diff hist +86 Retifanlimab-dlwr No edit summary
- 20:3220:32, 20 May 2024 diff hist +23 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 20:3120:31, 20 May 2024 diff hist +8,964 N Retifanlimab-dlwr Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue..."
- 20:1820:18, 20 May 2024 diff hist +14 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 20:1820:18, 20 May 2024 diff hist +3,936 N Tofersen Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=..." current
18 May 2024
- 16:0216:02, 18 May 2024 diff hist +18 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 16:0216:02, 18 May 2024 diff hist +22 Ritlecitinib No edit summary current
- 16:0116:01, 18 May 2024 diff hist +10,106 N Ritlecitinib Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=ritlecitinib |aOrAn=a |drugClass=janus kinase 3 (JAK3) inhibitor and also an inhibitor of the tyrosine kinase |indicationType=treatment |indication=severe alopecia areata in adults and adolescents 12 years of age and older |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, i..."
17 May 2024
- 17:2117:21, 17 May 2024 diff hist +17 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 17:2117:21, 17 May 2024 diff hist +8,825 N Quizartinib Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,..." current